Table 1.
Patient and disease baseline characteristics (n = 117).
| Parameter | Value |
| Age (years) | |
| Median (range) | 70 (60–87) |
| >70, n (%) | 67 (57) |
| ≥75, n (%) | 41 (35) |
| ECOG performance status, n (%) | |
| 0 | 11 (9.5) |
| 1 | 36 (31) |
| 2 | 47 (40) |
| 3 | 19 (16) |
| 4 | 4 (3.5) |
| HCT-CI score, n (%) | |
| Median (range) | 3 (0–10) |
| 0–2 | 48 (42) |
| ≥3 | 67 (58) |
| Sex, n (%) | |
| Female | 66 (56) |
| Male | 51 (44) |
| Bone marrow blasts count, n (%) | |
| 20–29% | 15 (13) |
| 30–50% | 41 (35) |
| ≥50% | 61 (52) |
| LDH serum activity >480 IU/L, n (%) | 51 (46) |
| Serum creatinine >1.3 mg/dL, n (%) | 23 (20) |
| Cytogenetic risk, n (%) | |
| Favorable | 8 (7) |
| Intermediate | 51 (43.5) |
| Adverse | 51 (43.5) |
| Lack of metaphases | 7 (6) |
| AML status, n (%) | |
| De novo | 79 (67.5) |
| Secondary | 38 (32.5) |
| Somatic mutation, n (%) | |
|
FLT3-ITD or TKD (1) NPM1(2) |
13 (11) 11 (9) |
| Coexistence of somatic mutations, n (%) | |
| FLT3-ITD and TKD (−), NPM1 (−) | 31 (26) |
| FLT3-ITD and TKD (−), NPM1 (+) | 4 (3) |
| FLT3-ITD or TKD (+), NPM1 (−) | 4 (3) |
| FLT3-ITD or TKD (+), NPM1 (+) | 6 (5) |
| Treatment for antecedent hematologic disorders, n (%) | |
| Azacitidine | 7 (6) |
| Hydroxyurea | 3 (3) |
| LD-AC and azacitidine | 1 (1) |
| not specified | 1 (1) |
(1) Data were available for 64 (55%) patients; (2) data were available for 47 (40%) patients. Abbreviations: AML, acute myeloid leukemia; ECOG, the Eastern Cooperative Oncology Group; HCT-CI, the hematopoietic cell transplantation comorbidity index; ITD, internal tandem duplication; LD-AC, low-dose cytarabine; LDH, lactate dehydrogenase; TKD, tyrosine kinase domain.